TIDMLPX 
 
RNS Number : 6633K 
Lipoxen PLC 
23 April 2010 
 

+---------------------------------+---------------------------------+ 
| For immediate release           |                   23 April 2010 | 
+---------------------------------+---------------------------------+ 
 
 
                                  Lipoxen PLC 
                          ('Lipoxen' or 'the Company') 
 
                                DIRECTOR DEALING 
 
Lipoxen PLC (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, is pleased to announce that further to the announcement released on 1 
April 2010, that the Company has raised GBP1.2 million through a non pre-emptive 
issue of shares (the "Fundraising"), certain directors have acquired ordinary 
shares of 0.5 pence each (the "New Ordinary Shares"). Details of the director 
dealings are set out in the table below: 
 
+--------------+----------+-----------+-----------+----------+ 
| Name         |    Date  |    Shares |     Total |     % of | 
|              |          |  acquired |  interest |    total | 
|              |          |           |           |   issued | 
|              |          |           |           |    share | 
|              |          |           |           |  capital | 
+--------------+----------+-----------+-----------+----------+ 
| Sir Brian    |  1 April | 1,071,429 | 2,262,606 |     1.32 | 
| Richards     |     2010 |           |           |          | 
+--------------+----------+-----------+-----------+----------+ 
| Scott        |  1 April |   535,714 | 1,301,362 |     0.76 | 
| Maguire      |     2010 |           |           |          | 
+--------------+----------+-----------+-----------+----------+ 
| Colin Hill   |  1 April |   535,714 | 1,675,420 |     0.97 | 
|              |     2010 |           |           |          | 
+--------------+----------+-----------+-----------+----------+ 
|              |          |           |           |          | 
+--------------+----------+-----------+-----------+----------+ 
 
                                    - Ends - 
 
For further information please contact: 
 
+------------------------------------------+--------------------+ 
| Lipoxen plc                              |     +44 (0)20 7389 | 
|                                          |               5015 | 
+------------------------------------------+--------------------+ 
| M. Scott Maguire, Chief Executive        |                    | 
| Officer                                  |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Singer Capital Markets (nominated        |     +44 (0)20 3205 | 
| adviser)                                 |               7500 | 
+------------------------------------------+--------------------+ 
| Jeff Keating / Claes Spång               |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Buchanan Communications                  |     +44 (0)20 7466 | 
|                                          |               5000 | 
+------------------------------------------+--------------------+ 
| Lisa Baderoon / Catherine Breen          |                    | 
+------------------------------------------+--------------------+ 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSKMGZDVZZGGZM 
 

Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Lipoxen 차트를 더 보려면 여기를 클릭.
Lipoxen (LSE:LPX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Lipoxen 차트를 더 보려면 여기를 클릭.